In view of the successful experience of this case, we suggest that dose-adjusted dabrafenib plus trametinib might be a potentially effective treatment strategy for elderly patients with advanced pancreatic adenocarcinoma harboring BRAF V600E mutations. Here, BRAF is linked to pancreatic adenocarcinoma.